SHARE
COPY LINK

BUSINESS

Maersk profits plummet as Yemeni attacks close off Red Sea route

Danish shipping giant Maersk posted a huge drop in net profit for the first quarter on Thursday as Yemeni rebel attacks are forcing it to avoid the vital Red Sea route.

Maersk profits plummet as Yemeni attacks close off Red Sea route
Maersk chief executive Vincent Clerc holds a press meeting to announce the company's results. Photo: Emil Helms/Ritzau Scanpix

Maersk reported a net profit of $177 million in the first three months of the year, a 13-fold drop from the same period last year. Turnover fell 13 percent to $12.4 billion, slightly lower than forecast by analysts surveyed by financial data firm FactSet.

The company, however, raised its outlook for the full year, citing higher demand and increased rates and costs due to the supply chain disruptions in the Red Sea.

It now expects an underlying core profit ranging between $4 billion and $6 billion, up from $1 billion-$6 billion previously.

“We had a positive start to the year with a first quarter developing precisely as we expected,” Maersk chief executive Vincent Clerc said in a statement.

“Demand is trending towards the higher end of our market growth guidance and conditions in the Red Sea remain entrenched,” he said.

“This not only supported a recovery in the first quarter compared to the previous quarter, but also provide an improved outlook for the coming quarters, as we now expect these conditions to stay with us for most of the year.”

Iran-backed Huthi rebels, who control the Yemeni capital Sanaa and much of the country’s Red Sea coast, have launched dozens of attacks on ships since November, claiming solidarity with Palestinians caught up in the Israel-Hamas war.

The United States in December announced a maritime security initiative to protect Red Sea shipping from the attacks, which have forced commercial vessels to divert from the route that normally carries 12 percent of global trade.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

BUSINESS

Weight-loss drug maker Novo Nordisk’s profits soar further

Danish pharmaceutical giant Novo Nordisk reported more soaring profits Thursday as it basks in the popularity of anti-diabetes and weight-loss drugs Ozempic and Wegovy which have turned it into Europe's most valuable company.

Weight-loss drug maker Novo Nordisk's profits soar further

Its net profit reached 25.4 billion kroner ($3.6 billion) in the first quarter, a 28 percent jump from the same period last year, the company said in a statement.

Sales rose by 24 percent at current exchange rates to 65.3 billion kroner — almost two-billion-kroner higher than forecast by analysts surveyed by Bloomberg and financial data firm FactSet.

Novo Nordisk raised its outlook for 2024, saying it now expects sales to rise by between 19 to 27 percent — up from 18-26 percent previously.

“More patients benefit from our innovative treatments,” Novo Nordisk chief executive Lars Fruergaard Jorgensen said in a statement.

To step up production for its blockbuster drugs, Novo Nordisk is acquiring US drug manufacturing firm Catalent.

“The agreement to acquire the three Catalent manufacturing sites will enable us to serve significantly more people living with diabetes and obesity in the future,” Fruergaard Jorgensen added.

Novo Nordisk produces Ozempic, an injectable anti-diabetic treatment which became wildly popular on social networks for its slimming properties.

It also makes Wegovy, which has the same active ingredient as Ozempic in a different dose and was approved by US regulators to treat obesity.

SHOW COMMENTS